Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
18°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Coherus Bio
(NQ:
CHRS
)
1.100
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Coherus Bio
< Previous
1
2
3
4
5
6
7
Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
November 07, 2024
Via
Benzinga
CHRS Stock Earnings: Coherus BioSciences Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
CHRS stock results show that Coherus BioSciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary
June 30, 2024
Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to...
Via
Talk Markets
CHRS Stock Earnings: Coherus BioSciences Misses EPS, Misses Revenue for Q1 2024
May 09, 2024
CHRS stock results show that Coherus BioSciences missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Why Coherus Biosciences Stock Tumbled on Thursday
March 14, 2024
The company fell well short of expectations for its fourth quarter.
Via
The Motley Fool
Recap: Coherus BioSciences Q4 Earnings
March 13, 2024
Via
Benzinga
Earnings Preview For Coherus BioSciences
March 12, 2024
Via
Benzinga
Earnings Scheduled For March 13, 2024
March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
Via
Benzinga
Why Coherus BioSciences Stock Jumped Today
February 06, 2024
As promised, Coherus is using the proceeds of a recent divestiture to pay down debt and reduce interest expenses.
Via
The Motley Fool
Why Coherus BioSciences Stock Is Sinking Today
January 23, 2024
The positive reaction to Coherus' sale of its ophthalmology franchise to Sandoz didn't last long.
Via
The Motley Fool
Why Coherus Biosciences Popped Today
January 22, 2024
Coherus is divesting its non-core ophthalmology franchise.
Via
The Motley Fool
Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 22, 2024
Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the...
Via
Benzinga
Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today?
January 22, 2024
Coherus BioSciences agreed to sell its ophthalmology franchise for $170M to Sandoz. This aligns with CHRS' focus on oncology and will help reduce debt and overhead costs.
Via
Benzinga
Why Is Cartesian Therapeutics (RNAC) Stock Down 5% Today?
January 22, 2024
Cartesian Therapeutics stock is falling on Monday as investors react to a delisting notice for RNAC shares due to its low trading price.
Via
InvestorPlace
Why Is B. Riley Financial (RILY) Stock Down 11% Today?
January 22, 2024
B. Riley Financial stock is falling on Monday as RILY investors react to reports of an SEC probe and the company's stance on the news.
Via
InvestorPlace
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Why Is Coherus BioSciences (CHRS) Stock Up 17% Today?
January 22, 2024
Coherus BioSciences stock is rising on Monday as CHRS investors react to a $170 million divestment of its CIMERLI ophthalmology franchise.
Via
InvestorPlace
Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
January 22, 2024
Shares of Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
January 22, 2024
We're starting the trading week with a breakdown of the biggest pre-market stock movers worth knowing about on Monday!
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
January 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
January 18, 2024
Via
Benzinga
Veradigm, Aehr Test Systems, Saratoga Investment And Other Big Stocks Moving Lower On Wednesday
January 10, 2024
U.S. stocks traded slightly higher, with the Dow Jones index gaining over 20 points on Wednesday. Shares of Veradigm Inc. (NASDAQ: MDRX) shares fell sharply during Wednesday’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
December 29, 2023
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention.
Via
Benzinga
FLJ Group, Bit Digital And Other Big Stocks Moving Higher In Friday's Pre-Market Session
December 29, 2023
U.S. stock futures were slightly higher this morning, with the Dow Jones futures gaining around 15 points on Thursday. Shares of FLJ Group Limited(NASDAQ: FLJ) rose sharply in pre-market trading.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Coherus BioSciences Stock Jumped Today
December 28, 2023
Coherus finally received FDA approval for its Udenyca OnBody injector system.
Via
The Motley Fool
Exposures
Product Safety
Crude Oil Falls Over 1%; First Wave BioPharma Shares Spike Higher
December 27, 2023
U.S. stocks traded mixed toward the end of trading, with the S&P 500 and Nasdaq Composite moving lower on Wednesday. The Dow traded up 0.05% to 37,564.54 while the NASDAQ fell 0.04% to 15,069.30. The...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
December 27, 2023
Shares of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) shares rose sharply during Wednesday’s session after Concentra sent an acquisition proposal to acquire 100% of equity of the company for $1.80 per...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
December 27, 2023
Via
Benzinga
Gold Gains 1%; Richmond Fed Manufacturing Index Falls In December
December 27, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 80 points on Wednesday. The Dow traded up 0.22% to 37,626.76 while the NASDAQ rose 0.06% to 15,084.02. The S&P...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Why Coherus BioSciences Stock Is Climbing Today
December 27, 2023
Coherus BioSciences, Inc. (NASDAQ: CHRS) shares are trading higher Wednesday after the company announced the FDA approval of its pegfilgrastim delivery device, Udenyca Onbody.
Via
Benzinga
Exposures
Product Safety
US Stocks Edge Higher; Coherus Reports FDA Approval Of UDENYCA ONBODY
December 27, 2023
U.S. stocks traded slightly higher this morning, with the Dow Jones index gaining more than 20 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.08% to 37,575.13 while...
Via
Benzinga
Topics
Stocks
Exposures
Product Safety
US Equities
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.